13th Mar 2019 11:00
Mereo BioPharma Group plc
("Mereo")
Mereo BioPharma announces the appointment of its CEO, Denise Scots-Knight, as a non-executive director to the Board of Elanco Animal Health Inc.
London, 13 March 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces that in accordance with AIM Rule 17, Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, has been appointed as a member of the Board of Directors at Elanco Animal Health Incorporated (NYSE: ELAN) with effect from 11 March 2019.
Elanco develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. The Company has approximately 5,800 employees. The Board of Directors was initially established in September 2018 when Elanco became a fully independent public company, following its separation from Eli Lilly and Company (NYSE:LLY).
For Further Enquiries:
Mereo | +44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer | |
Richard Jones, Chief Financial Officer | |
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Mereo) | +44 (0)20 7894 7000 |
Phil Davies | |
Will Goode | |
RBC Capital Markets (Joint Broker to Mereo) | +44 (0)20 7653 4000 |
Rupert Walford | |
Jamil Miah | |
FTI Consulting (Public Relations Adviser to Mereo) | |
Simon Conway | +44 (0)20 3727 1000 |
Brett Pollard | |
Burns McClellan (US Public Relations Adviser to Mereo) | +1 212 213 0006 |
Lisa Burns | |
Jill Steier |
About Mereo
Mereo is a biopharmaceutical company focused on the development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. In December 2018, Mereo announced the proposed combination of Mereo and OncoMed Pharmaceuticals, with the transaction expected to close in the second quarter of 2019. Each of Mereo's four product candidates has previously generated positive clinical data for Mereo's target indication or in a related indication. Since inception Mereo has commenced large, randomised, placebo-controlled Phase 2 clinical trials for all four of the product candidates:
· BPS-804 for osteogenesis imperfecta (OI). Mereo recently announced completion of enrolment with 112 adult patients in a Phase 2b dose ranging study with some initial data at the top dose expected in the Q2 2019 and top-line dose ranging data in late 2019. A pediatric Phase 3 study design has also been approved by the EMA. BPS-804 has orphan designation in the US and EU and has been accepted into the PRIME and Adaptive Pathways in EU;
· MPH-966 for alpha-1 antitrypsin deficiency (AATD). Mereo recently announced first patient in a Phase 2 dose ranging study in the US with data expected in late 2019;
· BCT-197 for acute exacerbations of COPD (AECOPD). Mereo announced positive Phase 2 data in May 2018; and
· BGS-649 for hypogonadotropic hypogonadism (HH). Mereo announced positive top-line Phase 2b data in March 2018 and positive results from the Phase 2b safety extension study in December 2018.
Related Shares:
MPH.L